Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer-Reference-Cited by-同舟云学术

Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer

Published:2005 Issue:1 Volume:68 Page:2-9
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Sternberg C.N.,Whelan P.,Hetherington J.,Paluchowska B.,Slee P.H.Th.J.,Vekemans K.,van Erps P.,Theodore C.,Koriakine O.,Oliver T.,Lebwohl D.,Debois M.,Zurlo A.,Collette L.

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference23 articles.

1. Satraplatin. GPC Biotech, Inc. Investigator Brochure, 2004, Princeton, NJ.

2. Highlights of contemporary issues in the medical management of prostate cancer

3. What's new in the treatment of advanced prostate cancer?

4. Treatment options in hormone resistant prostate cancer

5. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.

Cited by 201 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum^IV Complexes as Potent Antitumor Agents;Journal of Medicinal Chemistry;2024-05-22

2. Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions;Journal of Medicinal Chemistry;2024-04-09

3. Pyrenebutyrate Pt(IV) Complexes with Nanomolar Anticancer Activity;Pharmaceutics;2023-09-13

4. Emerging platinum(IV) prodrug nanotherapeutics: A new epoch for platinum-based cancer therapy;Journal of Controlled Release;2023-09

5. The current status in computational exploration of Pt(iv) prodrug activation by reduction;Physical Chemistry Chemical Physics;2023